Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Näytä muut versiot (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Bibliografiset tiedot
Päätekijät:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2008

Samankaltaisia teoksia

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Tekijä: Clerico, M, et al.
Julkaistu: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
Tekijä: Clerico, M, et al.
Julkaistu: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
Tekijä: Clerico, M, et al.
Julkaistu: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
Tekijä: Clerico, M, et al.
Julkaistu: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
Tekijä: Clerico, M, et al.
Julkaistu: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
Tekijä: Valéria Coelho Santa Rita Pereira, et al.
Julkaistu: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
Tekijä: Clerico, M, et al.
Julkaistu: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
Tekijä: Clerico, M, et al.
Julkaistu: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Tekijä: GJ Melendez-Torres, et al.
Julkaistu: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
Tekijä: E.J. Ramos González, et al.
Julkaistu: (2021-05-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
Tekijä: Clerico, M, et al.
Julkaistu: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
Tekijä: Clerico, M, et al.
Julkaistu: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
Tekijä: N. Y. Lasch
Julkaistu: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
Tekijä: Katarzyna Kapica-Topczewska, et al.
Julkaistu: (2019-01-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
Tekijä: G. Ya. Shvarts
Julkaistu: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Tekijä: Özlem Taşkapılıoğlu, et al.
Julkaistu: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Tekijä: Özlem Taşkapılıoğlu, et al.
Julkaistu: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Tekijä: Oscar Fernández
Julkaistu: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Tekijä: Massimiliano Mirabella, et al.
Julkaistu: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Tekijä: Mikhail Melnikov, et al.
Julkaistu: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
Tekijä: Methma Udawatta, et al.
Julkaistu: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Tekijä: Aaron Boster, et al.
Julkaistu: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
Tekijä: P Tappenden, et al.
Julkaistu: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
Tekijä: Anna Gil-Sánchez, et al.
Julkaistu: (2024-04-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
Tekijä: Genaro Gabriel Ortíz, et al.
Julkaistu: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
Tekijä: Arielle Kasindi, et al.
Julkaistu: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Tekijä: Arthur Komlosh, et al.
Julkaistu: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
Tekijä: Ioana S. Barac, et al.
Julkaistu: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Tekijä: T. E. Shmidt
Julkaistu: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
Tekijä: Ignacio Casanova, et al.
Julkaistu: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
Tekijä: Justin M. Honce, et al.
Julkaistu: (2020-09-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
Tekijä: Lyubomira Vlahova, et al.
Julkaistu: (2021-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Tekijä: Oliver Neuhaus, et al.
Julkaistu: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Tekijä: María I. Dominguez-Mozo, et al.
Julkaistu: (2022-06-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
Tekijä: Ümmügülsüm Koc, et al.
Julkaistu: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Tekijä: Fadi Towfic, et al.
Julkaistu: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Tekijä: Oreja-Guevara Celia, et al.
Julkaistu: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
Tekijä: Apfel Rainer, et al.
Julkaistu: (2008-09-01)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
Tekijä: Giannini Marta, et al.
Julkaistu: (2012-10-01)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
Tekijä: Javier Almeida, et al.
Julkaistu: (2017-11-01)